Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC labeling statement of identity, alcohol warning comprehension studies planned by FDA.

This article was originally published in The Tan Sheet

Executive Summary

OTC LABELING STATEMENT OF IDENTITY, ALCOHOL WARNING COMPREHENSION STUDIES will be conducted by FDA. Plans for two consumer surveys involving a total of 480 subjects were announced by the agency in the May 23 Federal Register. The notice also discussed FDA's plans to conduct two other labeling comprehension and preference studies involving 2,100 subjects ("The Tan Sheet" May 26, p. 4).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel